drugset / Trial / NCT04542382
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)
Phase 1
Completed
11 enrolled
University of California, San Francisco
Food and Drug Administration (FDA) · collab
Non-randomizedCrossoverOpen-labelBasic science
Summary
This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).
Timeline
- Start
- 2021-10-28
- Primary completion
- 2023-08-11
- Completion
- 2023-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | — |
| Subject | Rosuvastatin | Small molecule | 10 mg | — |
Indications
No indication recorded.